Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

被引：70

作者：

Pu, Dan ^{[1
]}

Yin, Liyuan ^{[1
]}

Huang, Lin ^{[1
]}

Qin, Changlong ^{[1
]}

Zhou, Yuwen ^{[2
]}

Wu, Qiang ^{[1
]}

Li, Yan ^{[1
]}

Zhou, Qinghua ^{[1
]}

Li, Lu ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Lung Canc Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

cyclooxygenase-2; immunotherapy; cancer; combination therapy; celecoxib; CELL LUNG-CANCER; PHASE-II TRIAL; PD-L1; EXPRESSION; PROGNOSTIC VALUE; CELECOXIB; COX-2; BIOMARKER; BLOCKADE; DRIVEN;

D O I：

10.3389/fonc.2021.637504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E-2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.

引用

页数：7

共 54 条

[21] PTGS2 (Cyclooxygenase-2) Expression and Survival among Colorectal Cancer Patients: A Systematic Review [J].

Kunzmann, Andrew T. ;

Murray, Liam J. ;

Cardwell, Chris R. ;

McShane, Charlene M. ;

McMenamin, Una C. ;

Cantwell, Marie M. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (09) :1490-1497

[22] Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials [J].

LaRocca, Christopher J. ;

Warner, Susanne G. .

CLINICAL AND TRANSLATIONAL MEDICINE, 2018, 7

[23] Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway [J].

Li, Ang ;

Chen, Ping ;

Leng, Ye ;

Kang, Jiuhong .

ONCOGENE, 2018, 37 (45) :5952-5966

[24] Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer [J].

Lilenbaum, Rogerio ;

Socinski, Mark A. ;

Altorki, Nasser K. ;

Hart, Lowell L. ;

Keresztes, Roger S. ;

Hariharan, Subramanian ;

Morrison, Mark E. ;

Fayyad, Rana ;

Bonomi, Phillip .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4825-4832

[25] Cigarette smoke extracts and cadmium induce COX-2 expression through γ-secretase-mediated p38 MAPK activation in C6 astroglia cells [J].

Lim, Hyun Joung ;

Park, Jung Hyun ;

Jo, Chulman ;

Yoon, Keejung ;

Koh, Young Ho .

PLOS ONE, 2019, 14 (02)

[26] Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity [J].

Loo, Tze Mun ;

Kamachi, Fumitaka ;

Watanabe, Yoshihiro ;

Yoshimoto, Shin ;

Kanda, Hiroaki ;

Arai, Yuriko ;

Nakajima-Takagi, Yaeko ;

Iwama, Atsushi ;

Koga, Tomoaki ;

Sugimoto, Yukihiko ;

Ozawa, Takayuki ;

Nakamura, Masaru ;

Kumagai, Miho ;

Watashi, Koichi ;

Taketo, Makoto M. ;

Aoki, Tomohiro ;

Narumiya, Shuh ;

Oshima, Masanobu ;

Arita, Makoto ;

Hara, Eiji ;

Ohtani, Naoko .

CANCER DISCOVERY, 2017, 7 (05) :522-538

[27] A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis [J].

Ma, Xinrong ;

Holt, Dawn ;

Kundu, Namita ;

Reader, Jocelyn ;

Goloubeva, Olga ;

Take, Yukinori ;

Fulton, Amy M. .

ONCOIMMUNOLOGY, 2013, 2 (01)

[28] Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity [J].

Mao, Yumeng ;

Sarhan, Dhifaf ;

Steven, Andre ;

Seliger, Barbara ;

Kiessling, Rolf ;

Lundqvist, Andreas .

CLINICAL CANCER RESEARCH, 2014, 20 (15) :4096-4106

[29] Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity [J].

Markosyan, Nune ;

Chen, Edward P. ;

Evans, Rebecca A. ;

Ndong, Victoire ;

Vonderheide, Robert H. ;

Smyth, Emer M. .

BREAST CANCER RESEARCH, 2013, 15 (05)

[30] Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting [J].

Matsushita, Hirokazu ;

Vesely, Matthew D. ;

Koboldt, Daniel C. ;

Rickert, Charles G. ;

Uppaluri, Ravindra ;

Magrini, Vincent J. ;

Arthur, Cora D. ;

White, J. Michael ;

Chen, Yee-Shiuan ;

Shea, Lauren K. ;

Hundal, Jasreet ;

Wendl, Michael C. ;

Demeter, Ryan ;

Wylie, Todd ;

Allison, James P. ;

Smyth, Mark J. ;

Old, Lloyd J. ;

Mardis, Elaine R. ;

Schreiber, Robert D. .

NATURE, 2012, 482 (7385) :400-U149

← 1 2 3 4 5 6 →